Lupin rose 3.64% to Rs 914.20 at 14:16 IST on BSE after net profit rose 42.03% to Rs 476.13 crore on 20.84% increase in total income to Rs 3054.41 crore in Q3 December 2013 over Q3 December 2012.
The result was announced during trading hours today, 3 February 2014.
Meanwhile, the BSE Sensex was down 210.32 points, or 1.03%, to 20,303.53.
On BSE, so far 2.29 lakh shares were traded in the counter, compared with an average volume of 59,750 shares in the past one quarter.
The stock hit a high of Rs 914 and a low of Rs 885 so far during the day. The stock hit a record high of Rs 951 on 6 January 2014. The stock hit a 52-week low of Rs 569 on 1 March 2013.
The stock had outperformed the market over the past one month till 31 January 2014, sliding 2.92% compared with the Sensex's 3.10% fall. The scrip had outperformed the market in past one quarter, falling 0.57% as against Sensex's 3.07% fall.
More From This Section
The large-cap company has an equity capital of Rs 89.66 crore. Face value per share is Rs 2.
Lupin is a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB and cephalosporin segment.
Powered by Capital Market - Live News